Markets
BSE See NSE See 38,040.57
15.12 (0.04%)
Data Bank

Data Bank

Print

To read the entire article, you must be a DSIJ magazine subscriber.

Current print subscribers click here to login

Subscribe now to get DSIJ All Access

Comments are only visible to subscribers.

DSIJ Mindshare

Glenmark to launch higher strength version of oral antiviral FabiFlu

Anthony Fernandes / Article rating: 4.7

Global pharma major, Glenmark Pharmaceuticals announced on Thursday that it is launching a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. Glenmark Pharmaceuticals was the first company in the country to have received the regulator’s approval for 400 mg dosage form.

12345Last